布鲁顿酪氨酸激酶
化学
酪氨酸激酶
共价键
激酶
体内
酪氨酸
癌症研究
药理学
生物化学
信号转导
医学
生物
遗传学
有机化学
作者
Daniela Angst,F. Gessier,Philipp Janser,Anna Vulpetti,Rudolf Wälchli,Christian Beerli,Amanda Littlewood‐Evans,Janet Dawson,Barbara Nuesslein‐Hildesheim,Grazyna Wieczorek,Sascha Gutmann,Clemens Scheufler,Alexandra Hinniger,Alfred Zimmerlin,Enrico G. Funhoff,Robert Pulz,Bruno Cenni
标识
DOI:10.1021/acs.jmedchem.9b01916
摘要
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI